Immunotherapy with rIL-2 currently represents one of the most interesting therapeutic approaches to tumors. Ten patients with advanced phase neoplasms (3 melanomas and 7 renal) were admitted to the study. The subcutaneous treatment regime with rIL-2 (Proleukin-Cetus). The aim of the study is to monitor the peripheral immunological modifications induced by rIL-2 treatments and to detect eventual parameters correlated with clinical response. Preliminary analysis of our data demonstrate: subcutaneous administration of rIL-2 is able to induce an important immunological stimulation in all patients treated; nevertheless there seems not to be correlation between immunological parameters considered and the patients clinical response.
|Translated title of the contribution||Interleukin-2: Biological characteristics and therapeutic potential in oncology|
|Number of pages||6|
|Publication status||Published - 1992|
ASJC Scopus subject areas